tiprankstipranks
Revolution Medicines (RVMD)
NASDAQ:RVMD
US Market
RVMD
Revolution Medicines
RESEARCH TOOLSreports
Want to see RVMD full AI Analyst Report?

Revolution Medicines (RVMD) Stock Forecast & Price Target

957 Followers
See the Price Targets and Ratings of:

RVMD Analyst Ratings

Strong Buy
21Ratings
Strong Buy
20 Buy
1 Hold
0 Sell
Based on 21 analysts giving stock ratings to
Revolution
Medicines
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

RVMD Stock 12 Month Forecast

Average Price Target

$248.65
▲(17.63% Upside)
Based on 21 Wall Street analysts offering 12 month price targets for Revolution Medicines in the last 3 months. The average price target is $248.65 with a high forecast of $320.00 and a low forecast of $179.00. The average price target represents a 17.63% change from the last price of $211.38.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"38":"$38","321":"$321","108.75":"$108.8","179.5":"$179.5","250.25":"$250.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":320,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$320.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":248.65,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$248.65</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":179,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$179.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[38,108.75,179.5,250.25,321],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,209.87,218.34153846153848,226.81307692307692,235.2846153846154,243.75615384615384,252.2276923076923,260.6992307692308,269.1707692307692,277.64230769230767,286.11384615384617,294.5853846153846,303.0569230769231,311.52846153846156,{"y":320,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,209.87,212.85307692307694,215.83615384615385,218.81923076923078,221.8023076923077,224.78538461538463,227.76846153846154,230.75153846153847,233.73461538461538,236.71769230769232,239.70076923076923,242.68384615384616,245.66692307692307,{"y":248.65,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,209.87,207.4953846153846,205.12076923076924,202.74615384615385,200.37153846153848,197.99692307692308,195.6223076923077,193.24769230769232,190.87307692307692,188.49846153846153,186.12384615384616,183.74923076923076,181.3746153846154,{"y":179,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":39.53,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.86,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.84,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.8,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.65,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97.16,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101.62,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 54,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.64,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":139.48,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 59,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":163.68,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 74,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":187.51,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":187.53,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 77,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":209.87,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$320.00Average Price Target$248.65Lowest Price Target$179.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on RVMD
Brian Cheng
J.P. Morgan
J.P. Morgan
$246
Buy
16.38%
Upside
Reiterated
09/01/26
J.P. Morgan Sticks to Their Buy Rating for Revolution Medicines (RVMD)
Needham Analyst forecast on RVMD
Ami Fadia
Needham
Needham
$240→$275
Buy
30.10%
Upside
Reiterated
08/31/26
Ami Fadia Raises RVMD Price Target to $275 on Strong Rasonque U.S. Launch Economics and Robust Oncology Pipeline
LifeSci Capital Analyst forecast on RVMD
Charles Zhu
LifeSci Capital
LifeSci Capital
$291→$315
Buy
49.02%
Upside
Reiterated
08/29/26
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (NASDAQ: RVMD) and Spyre Therapeutics (NASDAQ: SYRE)
UBS Analyst forecast on RVMD
Michael Yee
UBS
UBS
$220→$265
Buy
25.37%
Upside
Reiterated
08/28/26
UBS Reaffirms Their Buy Rating on Revolution Medicines (RVMD)
Jefferies Analyst forecast on RVMD
Faisal Khurshid
Jefferies
Jefferies
$270
Buy
27.73%
Upside
Reiterated
08/27/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Guggenheim Analyst forecast on RVMD
Michael Schmidt
Guggenheim
Guggenheim
$240→$275
Buy
30.10%
Upside
Reiterated
08/27/26
Analysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), HOYA (HOCPF)
Wells Fargo Analyst forecast on RVMD
Eva Fortea Verdejo
Wells Fargo
Wells Fargo
$240
Buy
13.54%
Upside
Assigned
08/27/26
Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (NASDAQ: KYMR), Revolution Medicines (NASDAQ: RVMD) and Spyre Therapeutics (NASDAQ: SYRE)
Evercore ISI Analyst forecast on RVMD
Cory Kasimov
Evercore ISI
Evercore ISI
$230→$320
Buy
51.39%
Upside
Reiterated
08/27/26
Revolution Medicines price target raised to $320 from $230 at Evercore ISIRevolution Medicines price target raised to $320 from $230 at Evercore ISI
Oppenheimer Analyst forecast on RVMD
Jay Olson
Oppenheimer
Oppenheimer
$230→$260
Buy
23.00%
Upside
Reiterated
08/27/26
Revolution Medicines price target raised to $260 from $230 at OppenheimerRevolution Medicines price target raised to $260 from $230 at Oppenheimer
H.C. Wainwright Analyst forecast on RVMD
Robert Burns
H.C. Wainwright
H.C. Wainwright
$195→$280
Buy
32.46%
Upside
Reiterated
08/27/26
Revolution Medicines price target raised to $280 from $195 at H.C. WainwrightRevolution Medicines price target raised to $280 from $195 at H.C. Wainwright
Truist Financial Analyst forecast on RVMD
Gregory Renza
Truist Financial
Truist Financial
$231→$239
Buy
13.07%
Upside
Reiterated
08/27/26
Analysts Offer Insights on Healthcare Companies: Zymeworks (NASDAQ: ZYME), Revolution Medicines (NASDAQ: RVMD) and Agilent (NYSE: A)
Stifel Nicolaus Analyst forecast on RVMD
Laura Prendergast
Stifel Nicolaus
Stifel Nicolaus
$215
Buy
1.71%
Upside
Reiterated
08/27/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wedbush Analyst forecast on RVMD
Robert Driscoll
Wedbush
Wedbush
$201→$225
Buy
6.44%
Upside
Reiterated
08/27/26
Analysts Offer Insights on Healthcare Companies: Incyte (NASDAQ: INCY) and Revolution Medicines (NASDAQ: RVMD)
Raymond James Analyst forecast on RVMD
Sean McCutcheon
Raymond James
Raymond James
$230→$248
Buy
17.32%
Upside
Reiterated
08/27/26
Revolution Medicines price target raised to $248 from $230 at Raymond JamesRevolution Medicines price target raised to $248 from $230 at Raymond James
RBC Capital Analyst forecast on RVMD
Leonid Timashev
RBC Capital
RBC Capital
$203→$251
Buy
18.74%
Upside
Assigned
08/26/26
RBC Capital Keeps Their Buy Rating on Revolution Medicines (RVMD)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on RVMD
Brian Cheng
J.P. Morgan
J.P. Morgan
$246
Buy
16.38%
Upside
Reiterated
09/01/26
J.P. Morgan Sticks to Their Buy Rating for Revolution Medicines (RVMD)
Needham Analyst forecast on RVMD
Ami Fadia
Needham
Needham
$240→$275
Buy
30.10%
Upside
Reiterated
08/31/26
Ami Fadia Raises RVMD Price Target to $275 on Strong Rasonque U.S. Launch Economics and Robust Oncology Pipeline
LifeSci Capital Analyst forecast on RVMD
Charles Zhu
LifeSci Capital
LifeSci Capital
$291→$315
Buy
49.02%
Upside
Reiterated
08/29/26
Analysts Offer Insights on Healthcare Companies: Revolution Medicines (NASDAQ: RVMD) and Spyre Therapeutics (NASDAQ: SYRE)
UBS Analyst forecast on RVMD
Michael Yee
UBS
UBS
$220→$265
Buy
25.37%
Upside
Reiterated
08/28/26
UBS Reaffirms Their Buy Rating on Revolution Medicines (RVMD)
Jefferies Analyst forecast on RVMD
Faisal Khurshid
Jefferies
Jefferies
$270
Buy
27.73%
Upside
Reiterated
08/27/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Guggenheim Analyst forecast on RVMD
Michael Schmidt
Guggenheim
Guggenheim
$240→$275
Buy
30.10%
Upside
Reiterated
08/27/26
Analysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), HOYA (HOCPF)
Wells Fargo Analyst forecast on RVMD
Eva Fortea Verdejo
Wells Fargo
Wells Fargo
$240
Buy
13.54%
Upside
Assigned
08/27/26
Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (NASDAQ: KYMR), Revolution Medicines (NASDAQ: RVMD) and Spyre Therapeutics (NASDAQ: SYRE)
Evercore ISI Analyst forecast on RVMD
Cory Kasimov
Evercore ISI
Evercore ISI
$230→$320
Buy
51.39%
Upside
Reiterated
08/27/26
Revolution Medicines price target raised to $320 from $230 at Evercore ISIRevolution Medicines price target raised to $320 from $230 at Evercore ISI
Oppenheimer Analyst forecast on RVMD
Jay Olson
Oppenheimer
Oppenheimer
$230→$260
Buy
23.00%
Upside
Reiterated
08/27/26
Revolution Medicines price target raised to $260 from $230 at OppenheimerRevolution Medicines price target raised to $260 from $230 at Oppenheimer
H.C. Wainwright Analyst forecast on RVMD
Robert Burns
H.C. Wainwright
H.C. Wainwright
$195→$280
Buy
32.46%
Upside
Reiterated
08/27/26
Revolution Medicines price target raised to $280 from $195 at H.C. WainwrightRevolution Medicines price target raised to $280 from $195 at H.C. Wainwright
Truist Financial Analyst forecast on RVMD
Gregory Renza
Truist Financial
Truist Financial
$231→$239
Buy
13.07%
Upside
Reiterated
08/27/26
Analysts Offer Insights on Healthcare Companies: Zymeworks (NASDAQ: ZYME), Revolution Medicines (NASDAQ: RVMD) and Agilent (NYSE: A)
Stifel Nicolaus Analyst forecast on RVMD
Laura Prendergast
Stifel Nicolaus
Stifel Nicolaus
$215
Buy
1.71%
Upside
Reiterated
08/27/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
Wedbush Analyst forecast on RVMD
Robert Driscoll
Wedbush
Wedbush
$201→$225
Buy
6.44%
Upside
Reiterated
08/27/26
Analysts Offer Insights on Healthcare Companies: Incyte (NASDAQ: INCY) and Revolution Medicines (NASDAQ: RVMD)
Raymond James Analyst forecast on RVMD
Sean McCutcheon
Raymond James
Raymond James
$230→$248
Buy
17.32%
Upside
Reiterated
08/27/26
Revolution Medicines price target raised to $248 from $230 at Raymond JamesRevolution Medicines price target raised to $248 from $230 at Raymond James
RBC Capital Analyst forecast on RVMD
Leonid Timashev
RBC Capital
RBC Capital
$203→$251
Buy
18.74%
Upside
Assigned
08/26/26
RBC Capital Keeps Their Buy Rating on Revolution Medicines (RVMD)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BTSGBrightSpring Health Services, Inc.
GPCRStructure Therapeutics, Inc. Sponsored ADR
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Revolution Medicines

3 Months
Joseph CatanzaroMizuho Securities
Success Rate
12/14 ratings generated profit
86%
Average Return
+25.18%
Copying Joseph Catanzaro's trades and holding each position for 3 Months would result in 85.71% of your transactions generating a profit, with an average return of +25.18% per trade.
1 Year
Michael SchmidtGuggenheim
Success Rate
18/18 ratings generated profit
100%
Average Return
+107.14%
Copying Michael Schmidt's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +107.14% per trade.
2 Years
Peter LawsonBarclays
Success Rate
13/13 ratings generated profit
100%
Average Return
+381.68%
Copying Peter Lawson's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +381.68% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RVMD Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
10
10
6
3
1
Buy
49
64
50
74
51
Hold
1
3
3
4
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
60
77
59
81
54
In the current month, RVMD has received 52 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. RVMD average Analyst price target in the past 3 months is 248.65.
Each month's total comprises the sum of three months' worth of ratings.

RVMD Financial Forecast

RVMD Earnings Forecast

Next quarter’s earnings estimate for RVMD is -$2.43 with a range of -$3.26 to -$2.12. The previous quarter’s EPS was -$3.06. RVMD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year RVMD has Performed in-line its overall industry.
Next quarter’s earnings estimate for RVMD is -$2.43 with a range of -$3.26 to -$2.12. The previous quarter’s EPS was -$3.06. RVMD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year RVMD has Performed in-line its overall industry.

RVMD Sales Forecast

Next quarter’s sales forecast for RVMD is $16.93M with a range of $0.00 to $55.90M. The previous quarter’s sales results were $0.00. RVMD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year RVMD has Performed in-line its overall industry.
Next quarter’s sales forecast for RVMD is $16.93M with a range of $0.00 to $55.90M. The previous quarter’s sales results were $0.00. RVMD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year RVMD has Performed in-line its overall industry.

RVMD Stock Forecast FAQ

What is RVMD’s average 12-month price target, according to analysts?
Based on analyst ratings, Revolution Medicines’s 12-month average price target is 248.65.
    What is RVMD’s upside potential, based on the analysts’ average price target?
    Revolution Medicines has 17.63% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is RVMD a Buy, Sell or Hold?
          Revolution Medicines has a consensus rating of Strong Buy which is based on 20 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Revolution Medicines’s price target?
            The average price target for Revolution Medicines is 248.65. This is based on 21 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $320.00 ,the lowest forecast is $179.00. The average price target represents 17.63% Increase from the current price of $211.38.
              What do analysts say about Revolution Medicines?
              Revolution Medicines’s analyst rating consensus is a Strong Buy. This is based on the ratings of 21 Wall Streets Analysts.
                How can I buy shares of RVMD?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.